HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 09/19/2012 -- Catalyst Pharmace (NCM:CPRX) reported EPS of -0.201. For the Current Fiscal year, the company is expected to report EPS of -0.16. For the Next Quarter and Next Year, the company is expected to report EPS of -0.04 and -0.20 respectively. At Current Market Price, CPRX is in distance of +33.35% from its 50-day Moving Average price of $1.4923 and +92.80% from its 200-day Moving Average price of $1.0322. Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX) shares increased 11.51% and closed at $1.55 in the last trading session. The 52 week trading range for the company is $0.50 – $1.97. The shares of the company fell 13% in the last one year. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy.
Can CPRX Continue To Move Higher? Find Out Here
DARA Biosciences, (NCM:DARA) is very active today and traded between $1.11 - 1.30 with total traded volume of 6424094 shares. At a current price of 1.27, DARA is +0.22 - +20.95% from the previous close of $1.05. Moreover, At Current Market Price, DARA is in distance of +62.94% from its 50-day Moving Average price of $0.7794 and +35.52% from its 200-day Moving Average price of $0.9371. DARA Biosciences Inc (NASDAQ:DARA) surged up 16.19% to $1.22 on a traded volume of 2.71 million shares. Recently, The Helsinn Group of Switzerland has entered into an exclusive agreement with DARA BioSciences Inc for U.S. commercial rights to Gelclair. Gelclair is an FDA-cleared product indicated for the treatment of oral mucositis. The Company intends to launch Gelclair in the first quarter of 2013.
Can DARA Continue To Move Higher? Find Out Here
Denison Mines Cor (AMEX:DNN) is +0.27 - +18.62% from the previous close of $1.45. It traded between $1.44 - 1.72 with total traded volume of 13831127 shares. Keep a close eye on DNN, as the stock has been showing unusual moves over the past weeks. At Current market price, DNN has recovered +112.35% from its 52-week Low of 0.81 and has Pulled back -16.91% from its 52-week high of 2.07. Denison Mines Corp (USA)(NYSEAMEX:DNN) shares climbed 10.34% to $1.60 in the early hour. The shares of the company had its target price cut by Raymond James from $1.80 to $1.70 in a research note issued to investors on Sept. 10. The firm currently has a market perform rating on the stock. The company is engaged in uranium mining and related activities, including acquisition, exploration and development of uranium bearing properties, extraction, processing, selling and reclamation.
How Should Investors React To DNN Now? Find Out Here
Anthera Pharmaceu (NGM:ANTH) reported EPS of -2.247. For the Current Fiscal year, the company is expected to report EPS of -1.12. For the Next Quarter and Next Year, the company is expected to report EPS of -0.18 and -0.65 respectively. At Current Market Price, ANTH is in distance of +26.29% from its 50-day Moving Average price of $0.9423 and -35.23% from its 200-day Moving Average price of $1.8372. Anthera Pharmaceuticals Inc(NASDAQ:ANTH) shares jumped 13.15% and closed at $1.05 in the last trading session. The company yesterday provided an update on regulatory discussions for the global development of blisibimod. End of Phase 2 discussions with the US Food and Drug Administration (FDA) have been completed and will allow for the submission of Phase 3 protocols and the initiation of registration studies. Earlier in 2012, Anthera received a written response from the European Medicines Agency (EMA) providing similar development feedback for the blisibimod program.
How Should Investors Trade ANTH Now? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)